Evidence map›Paper›PMID 39731346›Full record

ReviewCPT: pharmacometrics & systems pharmacology2025

Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection.

Clémence Boivin-Champeaux, Nieves Velez de Mendizabal, Aksana Jones, Scott Balsitis, Stephan Schmidt, Justin S Feigelman, Francine Johansson Azeredo

Abstract readReview
In one paragraph

Review in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Clémence Boivin-ChampeauxDepartment of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0009-0008-0325-9436
Nieves Velez de MendizabalClinical Pharmacology and Pharmacometrics, Gilead Sciences, Foster City, California, USA.
Aksana JonesClinical Pharmacology and Pharmacometrics, Gilead Sciences, Foster City, California, USA.ORCID 0000-0001-7359-6958
Scott BalsitisResearch Discovery Virology, Gilead Sciences, Foster City, California, USA.ORCID 0009-0006-5177-8789
Stephan SchmidtDepartment of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0000-0002-4998-1167
Justin S FeigelmanClinical Pharmacology and Pharmacometrics, Gilead Sciences, Foster City, California, USA.ORCID 0000-0002-6296-7087
Francine Johansson AzeredoDepartment of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0000-0003-3625-0186

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states. This tutorial elucidates essential considerations for establishing a disease modeling platform to facilitate informed decision-making in hepatitis B treatment strategies. We review several published models of varying complexity and describe the context that motivated each model's structure and assumptions. Several of the models are made available in an interactive RShiny app to demonstrate the influence of model choice and sensitivity to the choice of parameter values.

Indexed as

Hepatitis BHepatitis B, ChronicModels, BiologicalModels, TheoreticalAntiviral AgentsCarcinoma, HepatocellularDisease ProgressionHepatitis B virusHumansLiver NeoplasmsAntiviral Agentsdisease progressionHBVmathematical modelingviral dynamics

Identifiers

PMID39731346
PMCPMC11919268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.